Licensing revenue - Q2 revenue was boosted by $55.7 mln recognized from navenibart European licensing agreement
ORLADEYO sales - ORLADEYO revenue rose 1% y-o-y, with stronger growth (+10% y-o-y) on a comparable basis excluding European revenue
Pediatric launch - Initial shipments of ORLADEYO oral pellets for pediatric patients began in August, with strong prescription demand
Q2 revenue and profit rise
US biotechnology firm's Q2 revenue rose 34% yr/yr, driven by ORLADEYO and licensing revenue
Company posted Q2 operating profit of $98.5 mln, up from $29.8 mln a year ago
2026 total revenue guidance raised to $690 mln-$715 mln, ORLADEYO guidance maintained
Analyst coverage and valuation
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BioCryst Pharmaceuticals, Inc. is $19.00, about 110.6% above its August 4 closing price of $9.02
BCRX•
